BRIDGEWATER, N.J., May 29 /PRNewswire/ -- Ortho Biotech today announced that two clinical studies for DOXIL(R) (doxorubicin HCl pegylated liposome injection) will be presented at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago from May 30 to June 3, 2008.
"We are pleased that ASCO has accepted these data for presentation at the annual meeting," said Craig Tendler, M.D., Vice President, Medical Affairs, Oncology/Nephrology, Ortho Biotech Products, L.P. "Through our ongoing investigation of DOXIL, Ortho Biotech is committed to oncology clinical research and helping patients fight cancer."
About DOXIL(R)
DOXIL is indicated in combination with VELCADE(R) (bortezomib) for the treatment of patients with multiple myeloma who have not previously received VELCADE and have received at least one prior therapy, and for the treatment of patients with ovarian cancer whose disease has progressed or recurred after prior platinum based therapy.
IMPORTANT SAFETY INFORMATION
BOXED WARNINGS
Cardiotoxicity, infusion reaction, myelosuppression, liver impairment, Substitution
DOXIL is marketed in the United States by Ortho Biotech Products, L.P., and in Israel by Janssen-Cilag. Schering-Plough Corporation, under a licensing agreement, has exclusive rights to market the medication as CAELYX throughout the rest of the world, excluding Japan and Israel. For more information about DOXIL, please visit www.DOXIL.com.
About Ortho Biotech Products, L.P.
Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. Since it was founded in 1990, Ortho Biotech and its worldwide affiliates have earned a global reputation for researching, manufacturing and marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious illnesses. For more information, visit www.orthobiotech.com.
NOTE: This release corresponds to ASCO abstracts 8562 and 8563 and publication number 20505.
CONTACT: Stephanie Fagan of Ortho Biotech, +1-908-541-4029, office, or
+1-201-572-9581, cell, Sfagan@obius.jnj.com
Web site: http://www.orthobiotech.com/
http://www.DOXIL.com/
http://www.doxil.com/pdf/DOXIL_PI_Booklet.pdf/
